ArticleClinical drug investigation2025

Cost-Effectiveness of Pembrolizumab Monotherapy for High Programmed Death Ligand 1 Advanced or Metastatic Non-small Cell Lung Cancer Depends on Long-Term Survivors.

Zakile A Mfumbilwa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.